(The) in a note issued to investors on Tuesday, August 1st. Jefferies Group LLC set a €46.50 ($54.71) price objective on shares of Total SA and gave the stock a "neutral" rating in a research note on Monday, July 31st. Finally, Barclays PLC set a €84.00 ($98.82) price objective on shares of Vinci SA and gave the company a "buy" rating in a report on Monday, July 31st. Seven investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The firm presently has a "neutral" rating on the stock.
Shares of Total SA (EPA:FP) have received an average rating of "Buy" from the fifteen ratings firms that are now covering the firm, MarketBeat Ratings reports. Jefferies Group LLC set a €92.00 ($108.24) price target on shares of Sanofi SA and gave the company a "neutral" rating in a report on Friday, May 12th. Kepler Capital Markets set a €74.00 ($87.06) target price on shares of Vinci SA and gave the stock a "neutral" rating in a research report on Thursday, June 22nd. Deutsche Bank AG set a €96.00 ($112.94) price objective on shares of Sanofi SA and gave the company a "buy" rating in a report on Tuesday, May 2nd.
Shares of Sanofi SA (EPA:SAN) opened at 80.60 on Monday. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is €50.03 ($58.86). The stock has a 50 day moving average of €25.48 and a 200-day moving average of €25.74. The stock has a market capitalization of €106.49 billion and a P/E ratio of 14.74. Sanofi SA has a 1-year low of €62.50 and a 1-year high of €92.97.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Week Herald and is owned by of Week Herald. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and worldwide trademark and copyright law.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations.